Healthcare provider profile · identity verified

Maung Shein, MD

Internal Medicine · BROOKLYN, NY · NPI 1669993630

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	363	134
Amlodipine Besylate	Amlodipine Besylate	207	76
Losartan Potassium	Losartan Potassium	190	66
Lisinopril	Lisinopril	163	56
Levothyroxine Sodium	Levothyroxine Sodium	155	50
Tamsulosin Hcl	Tamsulosin Hcl	106	41
Baclofen	Baclofen	103	43
Famotidine	Famotidine	103	38
Ozempic	Semaglutide	102	20
Albuterol Sulfate Hfa	Albuterol Sulfate	93	57
Hydrochlorothiazide	Hydrochlorothiazide	92	33
Metformin Hcl Er	Metformin Hcl	89	38
Metoprolol Tartrate	Metoprolol Tartrate	77	29
Hydralazine Hcl	Hydralazine Hcl	74	21
Fluticasone Propionate	Fluticasone Propionate	68	34
Gabapentin	Gabapentin	66	32
Alvesco	Ciclesonide	63	37
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	60	19
Pantoprazole Sodium	Pantoprazole Sodium	57	33
Alendronate Sodium	Alendronate Sodium	51	25
Metformin Hcl	Metformin Hcl	48	17
Doxycycline Monohydrate	Doxycycline Monohydrate	46	37
Meloxicam	Meloxicam	44	19
Allopurinol	Allopurinol	43	16
Jardiance	Empagliflozin	43	18
Simvastatin	Simvastatin	41	14
Omeprazole	Omeprazole	39	14
Atenolol	Atenolol	38	18
Ibuprofen	Ibuprofen	36	16
Mupirocin	Mupirocin	36	27
Acetaminophen-Codeine	Acetaminophen With Codeine	35	suppressed
Glipizide	Glipizide	35	16
Glipizide Er	Glipizide	34	14
Rosuvastatin Calcium	Rosuvastatin Calcium	34	12
Breyna	Budesonide/Formoterol Fumarate	33	12
Furosemide	Furosemide	33	16
Metoprolol Succinate	Metoprolol Succinate	33	18
Lovastatin	Lovastatin	30	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	28	suppressed
Pregabalin	Pregabalin	28	suppressed
Carvedilol	Carvedilol	27	11
Clopidogrel	Clopidogrel Bisulfate	27	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Trazodone Hcl	Trazodone Hcl	24	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Prednisone	Prednisone	23	16
Sertraline Hcl	Sertraline Hcl	21	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Finasteride	Finasteride	19	suppressed
Victoza 2-Pak	Liraglutide	19	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	18	suppressed
Nabumetone	Nabumetone	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Montelukast Sodium	Montelukast Sodium	16	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	15	suppressed
Sucralfate	Sucralfate	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	15	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	11
Tramadol Hcl	Tramadol Hcl	13	suppressed
Cephalexin	Cephalexin	12	suppressed
Fluocinonide	Fluocinonide	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Humulin N	Insulin Nph Human Isophane	11	suppressed
Liraglutide	Liraglutide	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	11	suppressed
Xifaxan	Rifaximin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error